A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors

被引：0
|
作者：
Hanna Bailey
Jordan P. McPherson
Erin B. Bailey
Theresa L. Werner
Sumati Gupta
Julia Batten
Guru Reddy
Gajanan Bhat
Sunil Sharma
Neeraj Agarwal
机构：
[1] The University of Utah,Huntsman Cancer Institute
[2] Spectrum Pharmaceuticals,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Belinostat; PXD101; HDAC inhibitor; Pharmacokinetics; Metabolites; Elimination;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1059 / 1071
页数：12
相关论文
共 50 条
  • [1] A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors
    Bailey, Hanna
    McPherson, Jordan P.
    Bailey, Erin B.
    Werner, Theresa L.
    Gupta, Sumati
    Batten, Julia
    Reddy, Guru
    Bhat, Gajanan
    Sharma, Sunil
    Agarwal, Neeraj
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (05) : 1059 - 1071
  • [2] A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors
    Molife, Rhoda
    Lee, James
    Petrylak, Daniel
    Blumenschein, George, Jr.
    Lassen, Ulrik
    Clark, Jayme
    Yap, Timothy
    Rowen, Elin
    Ang, Jooern
    Crowley, Elizabeth
    Clarke, Anne
    Hawthorne, Thomas
    Buhl-Jensen, Peter
    De Bono, Johann
    Kelly, Wm Kevin
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3476S - 3476S
  • [3] A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors
    Kelly, W. K.
    Yap, T.
    Lee, J.
    Lassen, U.
    Crowley, E.
    Clarke, A.
    Hawthorne, T.
    Buhl-Jensen, P.
    de Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] PHASE I STUDY OF THE PHARMACOKINETICS AND TOLERABILITY OF EVEROLIMUS IN CHINESE PATIENTS WITH ADVANCED SOLID TUMORS
    Xu, B.
    Shen, L.
    Ye, D.
    Jappe, A.
    Cherfi, A.
    Wang, H.
    Yuan, R.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2010, 21 : 178 - 178
  • [5] A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors
    Yan, Zhao
    Zhu, Zhongling
    Li, Kai
    Chen, Peng
    Wang, Liuchun
    Huang, Chun
    Xue, Jinhuai
    Liu, Meijun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 955 - 961
  • [6] A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors
    Zhao Yan
    Zhongling Zhu
    Kai Li
    Peng Chen
    Liuchun Wang
    Chun Huang
    Jinhuai Xue
    Meijun Liu
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 955 - 961
  • [7] Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced refractory solid tumors.
    Hirte, H
    Moore, MJ
    Oza, AM
    Siu, LL
    Harris, H
    Maclean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [8] A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors
    Kelly, W.
    Petrylak, D.
    Blumenschein, G.
    Lassen, U.
    Jensen, P. Buhl
    DeBono, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 127 - 127
  • [9] Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors.
    Xu, B.
    Shen, L.
    Ye, D.
    Jappe, A.
    Wang, H.
    Yuan, R.
    Wu, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    Jonker, D. J.
    Rosen, L. S.
    Sawyer, M. B.
    de Braud, F.
    Wilding, G.
    Sweeney, C. J.
    Jayson, G. C.
    McArthur, G. A.
    Rustin, G.
    Goss, G.
    Kantor, J.
    Velasquez, L.
    Syed, S.
    Mokliatchouk, O.
    Feltquate, D. M.
    Kollia, G.
    Nuyten, D. S. A.
    Galbraith, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1413 - 1419
12345